Immune phenotyping of CD34 subsets. CD34⁺ HSPCs and CD304⁺ pDCs from plerixafor-mobilized leukapheresis products were purified by immunomagnetic selection and evaluated by flow cytometry. (A) Representative analysis of CD45RA and CD123 expression on purified CD34⁺ HSPCs and CD304⁺ pDCs. The percentages of CD34⁺CD45RA⁻CD123^+/− common myeloid progenitors CMPs and hematopoietic stem cells (magenta), CD34⁺CD45RA⁺CD123^+/− granulocyte/macrophage progenitors (GMPs) + common lymphoid progenitors (CLPs; blue), CD34⁺CD45RA⁺CD123⁺⁺ pro-DC2s (orange), and CD34^-CD45RA⁺CD123⁺⁺CD304⁺ pDCs (black) cells are shown. (B-K) Expression of CD303 (B; n = 16), CD304 (C; n = 3), CD36 (D; n = 3), CD218a (E; n = 3), CD62L (F; n = 2), CD133 (G; n = 3), CD117 (H; n = 3), CD49f (I; n = 3), clone 12G5 of CD184 (J; n = 7 for CD34⁺ HSPCs and n = 3 for pDCs) and clone 1D9 of CD184 (K; n = 9 for CD34⁺ HSPCs and n = 3 for pDCs) on the different CD34⁺ HSPC subsets and CD304⁺ pDCs. Representative histograms as well as plots of MFIRs and percentage of positive cells are shown for each antigen. The CD34⁺CD45RA⁺CD123⁺⁺ pro-DC2 cells preferentially mobilized by plerixafor express high levels of CD303, CD304, CD36, CD218a, CD62L, and CD184. MFIR, mean fluorescence intensity ratio. Statistical comparisons were performed using an unpaired 2-tailed Student t test. *P < .05, **P < .01, ***P < .001.